P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 11, 2010, Pages 1173-1182

  Farrell, Andrew W ^a   Gadeock, Safina ^a   Pupovac, Aleta ^a   Wang, Bin ^a   Jalilian, Iman ^a   Ranson, Marie ^a   Sluyter, Ronald ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

B lymphocyte; IgE receptor; Multiple myeloma; P2X receptor; Plasma cell; Purinergic receptor

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 3' O (4 BENZOYLBENZOYL)ADENOSINE TRIPHOSPHATE; A 438079; ADENOSINE TRIPHOSPHATE; CALCIUM ION; CD23 ANTIGEN; ETHIDIUM; MAGNESIUM ION; MESSENGER RNA; PURINERGIC P2X1 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X5 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CELL LABELING; CELL SCREENING; CELL SURFACE; COLORIMETRY; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR CALCIUM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHIDIUM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MULTIPLE MYELOMA; RECEPTORS, IGE; RECEPTORS, PURINERGIC P2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 77956289939     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2010.07.001     Document Type: Article

References (56)

1. Burnstock G. Purine and pyrimidine receptors. Cell. Mol. Life Sci. 2007, 64:1471-1483.
2. Yegutkin G. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008, 1783:673-694.
3. Jarvis M.F., Khakh B.S. ATP-gated P2X cation channels. Neuropharmacology 2009, 56:208-215.
4. Erb L., Liao Z., Seye C.I., Weisman G.A. P2 receptors: intracellular signaling. Pflugers Arch. 2006, 452:552-562.
5. Qu Y., Dubyak G.R. P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinergic Signal. 2009, 5:163-173.
6. 7 receptor: death or life?. Purinergic Signal. 2005, 1:219-227.
7. White N., Burnstock G. P2 receptors and cancer. Trends Pharmacol. Sci. 2006, 27:211-217.
8. Deli T., Csernoch L. Extracellular ATP and cancer-an overview with special reference to P2 purinergic receptors. Pathol. Oncol. Res. 2008, 14:219-231.
9. 7: a growth-promoting receptor-implications for cancer. Purinergic Signal. 2009, 5:251-256.
10. Gorodeski G.I. P2X7-mediated chemoprevention of epithelial cancers. Expert Opin. Ther. Targets 2009, 13:1313-1332.
11. Pellegatti P., Raffaghello L., Bianchi G., Piccardi F., Pitoia V., Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 2008, 3:e2599.
12. Martins I., Tesniere A., Kepp O., Michaud M., Schlemmer F., Senovilla L., Seror C., Metivier D., Perfettini J.L., Zitvogel L., Kroemer G. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009, 8:3723-3728.
13. 7 receptor-dependent ATP release from B16 melanoma cells. Biochim. Biophys. Acta 2010, 1800:40-46.
14. 7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J. Leukoc. Biol. 1998, 64:265-273.
15. Wiley J.S., Dubyak G.R. Extracellular adenosine triphosphate increases cation permeability of chronic lymphocytic leukemia lymphocytes. Blood 1989, 73:1316-1323.
16. 7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 2002, 99:706-708.
17. Wiley J.S., Dao-Ung L.P., Gu B.J., Sluyter R., Shemon A.N., Li C., Taper J., Gallo J., Manoharan A. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 2002, 359:1114-1119.
18. Gu B.J., Bendall L.J., Wiley J.S. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 1998, 92:946-951.
19. Le Gall S.M., Bobe P., Reiss K., Horiuchi K., Niu X.D., Lundell D., Gibb D.R., Conrad D., Saftig P., Blobel C.P. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, l-selectin, and tumor necrosis factor alpha. Mol. Cell. Biol. 2009, 20:1785-1794.
20. 7 receptors. Am. J. Physiol. Cell Physiol. 2000, 279:C1189-C1197.
21. Moon H., Na H.Y., Chong K.H., Kim T.J. P2X7 receptor-dependent ATP-induced shedding of CD27 in mouse lymphocytes. Immunol. Lett. 2006, 102:98-105.
22. 7 receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell type. Purinergic Signal. 2009, 5:385-394.
23. 7 receptors. J. Invest. Dermatol. 2005, 125:482-490.
24. Constantinescu P., Wang B., Kovacevic K., Jalilian I., Bosman G.J., Wiley J.S., Sluyter R. P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells. Biochim. Biophys. Acta 2010, 1798:1797-1804.
25. Skarratt K.K., Fuller S.J., Sluyter R., Dao-Ung L.P., Gu B.J., Wiley J.S. A 5' intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1% to 2% of the Caucasian population. FEBS Lett. 2005, 579:2675-2678.
26. Wareham K., Vial C., Wykes R.C., Bradding P., Seward E.P. Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells. Br. J. Pharmacol. 2009, 157:1215-1224.
27. 7 receptors. Int. Immunol. 2002, 14:1415-1421.
28. 7 receptors. Exp. Dermatol. 2010, 19:e151-e157.
29. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nuñez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
30. Genty V., Dine G., Dufer J. Phenotypical alterations induced by glucocorticoids in RPMI 8226 human myeloma cells. Leuk. Res. 2004, 28:307-313.
31. 7 receptor-induced pore formation in human THP-1 cells. J. Pharmacol. Exp. Ther. 2004, 308:1053-1061.
32. Michel A.D., Thompson K.M., Simon J., Boyfield I., Fonfria E., Humphrey P.P.A. Species and response dependent differences in the effects of MAPK inhibitors on P2X7 receptor function. Br. J. Pharmacol. 2006, 149:948-957.
33. 7 receptor. Br. J. Pharmacol. 2004, 142:1015-1019.
34. 7 receptor by a novel protein tyrosine kinase antagonist. Biochem. Biophys. Res. Commun. 2008, 365:515-520.
35. 7 receptor stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes. Immunol. Cell Biol. 2007, 85:68-72.
36. Yip L., Woehrie T., Corriden R., Hirsh M., Chen Y., Inoue Y., Ferrari V., Insel P.A., Jinger W.G. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009, 23:1685-1693.
37. 7 ATP receptor. J. Biol. Chem. 1999, 274:33206-33208.
38. Lemieux G.A., Blumenkron F., Yeung N., Zhou P., Williams J., Grammer A.C., Petrovich R., Lipsky P.E., Moss M.L., Werb Z. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. J. Biol. Chem. 2007, 282:14836-14844.
39. Weskamp G., Ford J.W., Sturgill J., Martin S., Docherty A.J., Swendeman S., Broadway N., Hartmann D., Saftig P., Umland S., Sehara-Fujisawa A., Black R.A., Ludwig A., Becherer J.D., Conrad D.H., Blobel C.P. ADAM10 is the principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. Nat. Immunol. 2006, 7:1293-1298.
40. Lee D.H., Park K.S., Kong I.D., Kim J.W., Han B.G. Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines. BMC Immunol. 2006, 7:22.
41. Sluyter R., Barden J.A., Wiley J.S. Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res. 2001, 304:231-236.
42. Eslick G.D., Thampan B.V., Nalos M., McLean A.S., Sluyter R. Circulating interleukin-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. Int. J. Cardiol. 2009, 137:81-83.
43. 7 channel. Am. J. Physiol. Cell Physiol. 1998, 275:C1224-C1231.
44. 7 receptor: greatly increased function compared to human erythrocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R2090-R2098.
45. 7 receptor pharmacology in two human ostoblast-like cell lines. Br. J. Pharmacol. 2009, 156:1124-1135.
46. Zhang X., Meng L., He B., Chen J., Liu P., Zhao J., Zhang Y., Li M., An D. The role of P2X7 receptor in ATP-mediated human leukemia cell death: calcium-influx dependent. Acta Biochim. Biophys. Sin (Shanghai) 2009, 41:362-369.
47. Chessell I.P., Hatcher J.P., Bountra C., Michel A.D., Hughes J.P., Green P., Egerton J., Murfin M., Richardson J., Peck W.L., Grahames C.B., Casula M.A., Yiangou Y., Birch R., Anand P., Buell G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005, 114:386-396.
48. 7 receptors. J. Biol. Chem. 2001, 276:125-132.
49. Chen L., Brosnan C.F. Regulation of immune response by P2X7 receptor. Crit. Rev. Immunol. 2006, 26:499-513.
50. Thunberg U., Tobin G., Johnson A., Soderberg O., Padyukov L., Hultdin M., Klareskog L., Enblad G., Sundstrom C., Roos G., Rosenquist R. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 2002, 360:1935-1939.
51. Di Virgilio F., Wiley J.S. The P2X7 receptor of CLL lymphocytes - a molecule with a split personality. Lancet 2002, 360:1898-1899.
52. Sellick G.S., Rudd M., Eve P., Allinson R., Matutes E., Catovsky D., Houlston R.S. The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. Cancer Epidemiol. Biomark. Prev. 2004, 13:1065-1067.
53. Paneesha S., Starczynski J., Pepper C., Delgado J., Hooper L., Fegan C., Pratt G. The P2X7 receptor gene polymorphism 1513A > C has no effect on clinical prognostic markers and survival in multiple myeloma. Leuk. Lymphoma 2006, 47:281-284.
54. 7 receptor. J. Biol. Chem. 2001, 276:11135-11142.
55. 7 receptor does not affect its electrophysiological phenotype. Am. J. Physiol. Cell Physiol. 2003, 284:C749-C756.
56. 7 receptor polymorphism impairs extracellular adenosine 5'-triphosphate-induced interleukin-18 release from human monocytes. Genes Immun. 2004, 5:588-591.